Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for UCAR T-cell therapy targeting CD19/BCMA in relapse/refractory autoimmune diseases. The study includes several conditions and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Autoimmune Hemolytic Anemia
• Igg4-related Disease
• Inflammatory Myopathy
• Myasthenia Gravis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• UCAR T-cell therapy targeting CD19/BCMA

Snippet

Sponsor: Changzhou No.2 People's Hospital | Conditions: Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Status: NOT_YET_RECRUITING